PET and restaging of malignant lymphoma including residual masses and relapse

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue SUPPL. 1, 2003, Pages

  Reske, S N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

FDG; PET; Residual lymphoma; Scar tissue

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BIOCHEMISTRY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; SCAR;

EID: 0038409977     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1167-4     Document Type: Article

References (25)

1. Dalla-Favera R, Gaidano GL. Lymphomas. In: De Vita VT, Rontrey SA, eds. Cancer, principles of oncology. Philadelphia: Lippincott Williams and Wilkins; 2001:2215-2387.
2. Aisenberg A. Problems in Hodgkin's disease management. Blood 1999; 93:761-779.
3. Reiser M, Diehl V. Current treatment of follicular nonHodgkin's lymphoma. Eur J Cancer 2002; 38:1167-1172.
4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931-933.
5. 18F-FDG PET. J Nucl Med 2002; 43:1028-1030.
6. Hoskin P. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29:449-451.
7. Segall G. FDG PET imaging in patients with lymphoma: a clinical perspective. J Nucl Med 2001; 42:609-610.
8. DeWit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld D. Whole-body PET for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8:57-60.
9. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
10. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999; 38:799-804.
11. Bangerter M, Moog F, Griesshammer M, et al. Role of wholebody FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment. Radiography 1999; 5:155-163.
12. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302-310.
13. Cremerius U, Fabry U, Kroll U, et al. Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen Lymphomen Ergebnisse einer retrospektiven Studie an 72 Patienten. Nuklearmedizin 1999; 38:24-30.
14. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
15. 18fluordeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 26:200-206.
16. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613-618.
17. 18F)-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 15:272-278.
18. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
19. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's dis-ease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793-800.
20. Weihrauch M, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using F-18-FDG for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930-2934.
21. 18F)2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16:260-267.
22. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12:29-37.
23. 18F]-2-fluoro-2-deoxy-Dglucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731-743.
24. 18F-FDGPET. Fortschr Röntgenstr 1996; 165:309-310.
25. 18F)FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Q J Nucl Med 2001; 45:269-273.